Derm Rev
GLP-1R agonists in obesity management GLP-1R agonists, such as semaglutide, liraglutide, and tirzepatide, have gained prominence in the treatment of obesity
Both are designed for single use
This global innovation is now accessible at a nominal therapy cost of Rs 1850 per pen, enabling wider access to patients living with type 2 diabetes mellitus.
in the LEADER, REWIND, EXSCEL, ELIXA and SUSTAIN-6 trials were no significant difference in HF hospitalization between GLP-1 receptor agonist and placebo group ( However, meta-analysis encompassing eight CVOTs showed positive impact of GLP-1 receptor agonists on heart failure in patients with type 2 diabetes (T2D)
Other symptoms come from a lack of nutrients, due to the failure of your intestine to digest food properly